

EMA/88202/2018

## European Medicines Agency decision

P/0078/2018

of 16 March 2018

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for adeno-associated viral vector serotype rh.10 carrying the human N-sulfoglucosamine sulfohydrolase cDNA (LYS-SAF302) (EMEA-002122-PIP02-17) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

### **Disclaimer**

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

**Only the English text is authentic.**

# European Medicines Agency decision

P/0078/2018

of 16 March 2018

on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for adeno-associated viral vector serotype rh.10 carrying the human N-sulfoglucosamine sulfohydrolase cDNA (LYS-SAF302) (EMEA-002122-PIP02-17) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004<sup>1</sup>,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency<sup>2</sup>,

Having regard to the application submitted by LYSOGENE on 20 March 2017 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 26 January 2018, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.
- (4) It is therefore appropriate to adopt a decision granting a waiver.

---

<sup>1</sup> OJ L 378, 27.12.2006, p.1.

<sup>2</sup> OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

**Article 1**

A paediatric investigation plan for adeno-associated viral vector serotype rh.10 carrying the human N-sulfoglucosamine sulfohydrolase cDNA (LYS-SAF302), solution for infusion, intracerebral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

**Article 2**

A deferral for adeno-associated viral vector serotype rh.10 carrying the human N-sulfoglucosamine sulfohydrolase cDNA (LYS-SAF302), solution for infusion, intracerebral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 3**

A waiver for adeno-associated viral vector serotype rh.10 carrying the human N-sulfoglucosamine sulfohydrolase cDNA (LYS-SAF302), solution for infusion, intracerebral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 4**

This decision is addressed to LYSOGENE, 18-20 rue Jacques Dulud, 92200 - Neuilly sur Seine, France.



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

EMA/PDCO/757593/2017

London, 26 January 2018

## Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver

EMA-002122-PIP02-17

### Scope of the application

#### Active substance(s):

Adeno-associated viral vector serotype rh.10 carrying the human N-sulfoglucosamine sulfohydrolase cDNA (LYS-SAF302)

#### Condition(s):

Treatment of mucopolysaccharidosis type IIIA

#### Pharmaceutical form(s):

Solution for infusion

#### Route(s) of administration:

Intracerebral use

#### Name/corporate name of the PIP applicant:

LYSOGENE

### Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, LYSOGENE submitted for agreement to the European Medicines Agency on 20 March 2017 an application for a paediatric investigation plan for the above mentioned medicinal product and a waiver under Article 13 of said Regulation.

The procedure started on 25 April 2017.

Supplementary information was provided by the applicant on 6 November 2017. The applicant proposed modifications to the paediatric investigation plan and requested a deferral.



## Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
  - to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
  - to grant a deferral in accordance with Article 21 of said Regulation;
  - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(a) of said Regulation, on the grounds that the specific medicinal product is likely to be ineffective or unsafe in part or all of the paediatric population.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

## **Annex I**

**The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)**

# 1. Waiver

## 1.1. Condition:

Treatment of mucopolysaccharidosis type IIIA

The waiver applies to:

- adolescents from 12 to less than 18 years of age;
- solution for infusion, intracerebral use;
- on the grounds that the specific medicinal product is likely to be ineffective.

The waiver applies to:

- children from birth to less than 6 months of age;
- solution for infusion, intracerebral use;
- on the grounds that the specific medicinal product is likely to be unsafe.

# 2. Paediatric investigation plan

## 2.1. Condition:

Treatment of mucopolysaccharidosis type IIIA

### 2.1.1. Indication(s) targeted by the PIP

LYS-SAF302 is indicated for the treatment of children with Sanfilippo Type A Syndrome

### 2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 months to less than 12 years of age.

### 2.1.3. Pharmaceutical form(s)

Solution for infusion

### 2.1.4. Measures

| Area                    | Number of measures | Description                                                          |
|-------------------------|--------------------|----------------------------------------------------------------------|
| Quality-related studies | 1                  | <b>Study 1</b><br>Device compatibility study – solution for infusion |

| Area                                            | Number of measures | Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|-------------------------------------------------|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Non-clinical studies                            | 4                  | <p><b>Study 2</b></p> <p>Long-term (up to 6 months) juvenile MPS IIIA mice efficacy study</p> <p><b>Study 3</b></p> <p>Juvenile dog brain distribution study to evaluate the effect of various infusion volumes and rates on brain distribution (up to 4 weeks).</p> <p><b>Study 4</b></p> <p>Juvenile toxicity study in Cynomolgus monkeys to characterize the brain distribution of LYS-SAF302 (up to 4 weeks).</p> <p><b>Study 5</b></p> <p>Safety study in Cynomolgus monkeys (up to 5 weeks).</p> |
| Clinical studies                                | 1                  | <p><b>Study 6</b></p> <p>Open-label, single dose, single-time administration (via 6 different intraparenchymal injections), historically controlled trial to evaluate efficacy of LYS-SAF302 in children from 6 months to less than 12 years of age with severe MPS IIIA.</p>                                                                                                                                                                                                                          |
| Extrapolation, modelling and simulation studies | 0                  | Not applicable.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Other studies                                   | 0                  | Not applicable.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Other measures                                  | 0                  | Not applicable.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

### 3. Follow-up, completion and deferral of PIP

|                                                                                       |                 |
|---------------------------------------------------------------------------------------|-----------------|
| Concerns on potential long term safety/efficacy issues in relation to paediatric use: | No              |
| Date of completion of the paediatric investigation plan:                              | By October 2024 |
| Deferral for one or more measures contained in the paediatric investigation plan:     | Yes             |